Lexeo Therapeutics, Inc.
LXEO
$4.84
-$0.12-2.42%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 19.03M | 15.70M | 16.21M | 15.70M | 14.72M |
| Gross Profit | -19.03M | -15.70M | -16.21M | -15.70M | -14.72M |
| SG&A Expenses | 8.99M | 6.63M | 6.91M | 5.95M | 15.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.02M | 22.33M | 23.12M | 21.65M | 30.69M |
| Operating Income | -28.02M | -22.33M | -23.12M | -21.65M | -30.69M |
| Income Before Tax | -25.87M | -20.20M | -20.92M | -20.28M | -26.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.87M | -20.20M | -20.92M | -20.28M | -26.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.87M | -20.20M | -20.92M | -20.28M | -26.10M |
| EBIT | -28.02M | -22.33M | -23.12M | -21.65M | -30.69M |
| EBITDA | -27.87M | -22.18M | -22.96M | -21.50M | -30.55M |
| EPS Basic | -0.30 | -0.25 | -0.27 | -0.33 | -0.60 |
| Normalized Basic EPS | -0.19 | -0.16 | -0.17 | -0.21 | -0.42 |
| EPS Diluted | -0.30 | -0.25 | -0.27 | -0.33 | -0.60 |
| Normalized Diluted EPS | -0.19 | -0.16 | -0.17 | -0.21 | -0.42 |
| Average Basic Shares Outstanding | 85.63M | 81.18M | 76.36M | 60.98M | 43.57M |
| Average Diluted Shares Outstanding | 85.63M | 81.18M | 76.36M | 60.98M | 43.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |